Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RB1
REST API REST API
Homo sapiens
RB1 is differentially expressed in 318 experiments: 104 organism parts: liver, blood, ... (102 more);, 199 disease states: normal, Burkitt's lymphoma, ... (197 more);, 104 cell types 435 cell lines 45 compound treatments and 74 other conditions.
Synonyms RB, OSRC
Orthologs Rb1 (Rattus norvegicus)   RB1 (Bos taurus)   Rbf (Drosophila melanogaster)   RB1 (Gallus gallus)   Rbf2 (Drosophila melanogaster)   rb1 (Danio rerio)   Rb1 (Mus musculus)   LOC100493114 (Xenopus laevis)   ENSXETG00000034017 (Xenopus laevis)   Q9N122_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term negative regulation of S phase of mitotic cell cycle, neuron differentiation, negative regulation of cell growth, cell division, phosphorylation, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, maintenance of mitotic sister chromatid cohesion, negative regulation of cell proliferation, negative regulation of protein kinase activity, transcription, DNA-dependent, negative regulation of smoothened signaling pathway, mitotic cell cycle, kinase binding, cell cycle arrest, cell morphogenesis involved in neuron differentiation, G1 phase of mitotic cell cycle, regulation of mitotic cell cycle, positive regulation of mitotic metaphase/anaphase transition, transcription factor binding, molecular_function, G1 phase, Ras protein signal transduction, sister chromatid biorientation, positive regulation of transcription from RNA polymerase II promoter, spindle, neuron projection development, transcription coactivator activity, regulation of cell cycle, G1/S transition of mitotic cell cycle, nucleus, chromatin remodeling, Rb-E2F complex, kinase activity, transcription factor complex, phosphoprotein binding, chromatin, nucleoplasm, cell cycle checkpoint, negative regulation of transcription from RNA polymerase II promoter, S phase of mitotic cell cycle, negative regulation of epithelial cell proliferation, enzyme binding, negative regulation of cell cycle, neuron apoptosis, positive regulation of transcription, DNA-dependent, digestive tract development, ubiquitin protein ligase binding, androgen receptor binding, androgen receptor signaling pathway, striated muscle cell differentiation, neuron maturation, SWI/SNF complex, enucleate erythrocyte differentiation, myoblast differentiation, regulation of lipid kinase activity, protein localization to chromosome, centromeric region, interspecies interaction between organisms, PML body, regulation of S phase of mitotic cell cycle, positive regulation of macrophage differentiation, sequence-specific DNA binding transcription factor activity, M phase, mitotic cell cycle G1/S transition checkpoint, regulation of transcription involved in G1/S phase of mitotic cell cycle, negative regulation of sequence-specific DNA binding transcription factor activity, regulation of cohesin localization to chromatin, negative regulation of transcription involved in G1/S phase of mitotic cell cycle, RNA polymerase II activating transcription factor binding, regulation of centromere complex assembly
InterPro Term Cyclin-like, RB_A, RB_B, Rb_C, DUF3452_retinoblatoma-assoc
UniProt Accession Q6LE81, Q6LE82, Q6LE80, Q6LE77, Q6LE79, Q6LE65, Q6DUF0, Q7KZ60, Q7KZ61, P06400, P78495, B4DRB3, Q92728, F5H6G1
Gene-Disease Assocation BLADDER CANCER, OSTEOGENIC SARCOMA, SMALL CELL CANCER OF THE LUNG, RETINOBLASTOMA; RB1
Search EB-eye ENSG00000139687
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, E-GEOD-3526, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (42 experiments)

Factor Value U/D Experiments
SW480
4
E-MTAB-37, E-MEXP-1014, E-GEOD-18005, E-GEOD-2509
Jurkat
3
E-GEOD-1880, E-MEXP-2197, E-MTAB-62
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
T84
2
E-MTAB-37, E-GEOD-1474
429 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-TABM-34, ... (54 experiments)

Factor Value U/D Experiments
monocyte
1
3
E-GEOD-22373, E-MEXP-583, E-GEOD-8286, E-GEOD-5099
human foreskin fibroblast
2
E-GEOD-18147, E-GEOD-18265
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
memory B cell
2
E-TABM-702, E-MEXP-2360
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
1
2
E-MEXP-1600, E-AFMX-5, E-TABM-145
98 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-GEOD-12254, E-MEXP-2280, ... (66 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-21912, E-GEOD-20602, E-GEOD-8121
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-GEOD-6014
astrocytoma
2
E-GEOD-4290, E-MTAB-62
lymphoma
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-MTAB-37
prostate carcinoma
2
E-GEOD-96, E-MEXP-2034
193 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-1417, E-GEOD-697, E-GEOD-3720, ... (28 experiments)

Factor Value U/D Experiments
none
5
7
E-GEOD-5824, E-GEOD-412, E-GEOD-2803, E-MEXP-1958, E-MEXP-1230, ... (12 experiments)
glutamine
2
E-MEXP-1335, E-MEXP-941
control
2
E-GEOD-3284, E-GEOD-4006
sapphyrin PCI-2052
1
E-GEOD-6400
4OH-tamoxifen
1
E-GEOD-2292
4-hydroxytamoxifen
2
1
E-MEXP-2241
39 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-22513, E-GEOD-860, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

Developmental stage
studied in E-GEOD-5999, E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-TABM-868, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-TABM-127, E-GEOD-20540, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (41 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Processing time: 0.423 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM